12091692

Halozyme filed a patent infringement and declaratory judgment action against Merck in the District of New Jersey. The '692 patent is one of 15 patents-in-suit asserted against Merck's subcutaneous Keytruda, appearing as Count 10. The case remains pending, with the complaint and Merck's answer as the primary substantive filings.

Merck filed a petition for post-grant review challenging all claims 1–40 of U.S. Patent 12,091,692 B2. The PTAB instituted review on October 10, 2025, on written description, enablement, and obviousness grounds. A motion to terminate based on an alleged undisclosed real party-in-interest remains pending.